As ri­vals stum­ble, Pfiz­er boasts of a sec­ond 'break­through' on PhI­II RSV vac­cine

Pfiz­er has picked up fresh brag­ging rights for its big RSV vac­cine dri­ve.

The phar­ma gi­ant to­day spot­light­ed its sec­ond break­through drug des­ig­na­tion for PF-06928316, or RSVpreF, for peo­ple 60 and over. That lands just a few weeks af­ter their first BTD came through for in­fants.

The lat­est reg­u­la­to­ry win has the po­ten­tial for keep­ing the ball rolling at the FDA as Pfiz­er push­es ahead with its piv­otal Phase III study in the old­er age brack­et, which launched last fall. It al­so il­lus­trates the stark dif­fer­ence in for­tunes for this pro­gram com­pared to the ri­val GSK ef­fort, as well as the col­lab­o­ra­tion be­tween Sanofi and As­traZeneca for nir­se­vimab, which un­ex­pect­ed­ly was tagged with mixed Phase III re­sults re­cent­ly.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER